相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effects of Postponing Treatment in the Second Year of Cladribine Administration: Clinical Trial Simulation Analysis of Absolute Lymphocyte Counts and Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis
Nadia Terranova et al.
CLINICAL PHARMACOKINETICS (2019)
Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Potential mechanisms of action related to the efficacy and safety of cladribine
David Baker et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis
Stuart Cook et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies
Zhifeng Mao et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Pulsed immune reconstitution therapy in multiple sclerosis
Per Soelberg Sorensen et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2019)
Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers
Olaf Stuve et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2019)
Cladribine versus fingolimod, natalizumab and interferon for multiple sclerosis
Tomas Kalincik et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Cladribine versus fingolimod, natalizumab and interferon for multiple sclerosis
Tomas Kalincik et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells
Bryan Ceronie et al.
JOURNAL OF NEUROLOGY (2018)
Cladribine tablets added to IFN-β in active relapsing MS The ONWARD study
Xavier Montalban et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2018)
Data quality evaluation for observational multiple sclerosis registries
Tomas Kalincik et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Data quality evaluation for observational multiple sclerosis registries
Tomas Kalincik et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
David Baker et al.
EBIOMEDICINE (2017)
Observational data: Understanding the real MS world
Tomas Kalincik et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Observational data: Understanding the real MS world
Tomas Kalincik et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Defining reliable disability outcomes in multiple sclerosis
Tomas Kalincik et al.
BRAIN (2015)
Predictors of disease activity in 857 patients with MS treated with interferon beta-1b
Hans-Peter Hartung et al.
JOURNAL OF NEUROLOGY (2015)
Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial
Thomas P. Leist et al.
LANCET NEUROLOGY (2014)
Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis
Ilana Katz Sand et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study
Giancarlo Comi et al.
JOURNAL OF NEUROLOGY (2013)
Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study
Kottil Rammohan et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2012)
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Chris H. Polman et al.
ANNALS OF NEUROLOGY (2011)
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis
Gavin Giovannoni et al.
LANCET NEUROLOGY (2011)
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
Gavin Giovannoni et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
MSBase:: an international, online registry and platform for collaborative outcomes research in multiple sclerosis
H. Butzkueven et al.
MULTIPLE SCLEROSIS (2006)
分享论文
